AbbVie continues gains for seven straight sessions

AbbVie (NYSE:ABBV) continued gains for seven straight sessions, as the stock closed 1.3% higher at $189.90 on Friday.

The North Chicago-based pharma giant gained about 1% in the preceding six sessions. The stock has gained nearly 7% so far this year, compared to the near 1% rise in the broader S&P 500 Index.

ABBV, maker of Humira arthritis therapy, is up 1.4% over the past one month. The stock closed marginally higher on Thursday at $187.47.

Looking at Seeking Alpha’s Quant Rating, ABBV has a Hold rating with a score of 3.23 out of 5. The company received A+ in the prospect of profitability and a D- in growth factor.

Turning to the Wall Street community, 16 analysts gave ABBV a Buy and above. 12 analysts have given the stock a Hold recommendation, and no one recommended Sell or lower.

Seeking Alpha analysts are also bullish and see the stock as a Buy.

“AbbVie reported solid Q1 2025 results, raising full-year guidance and showing strong growth in Skyrizi and Rinvoq offsetting Humira’s decline,” pointed out Seeking Alpha analyst Daniel Schönberger. However, he added that despite entering the obesity market, AbbVie’s pipeline is early-stage and faces tough competition, so “meaningful revenue contribution is years away.”